Nanosized dendritic cell membrane vesicles (DC‐MVs) are examined as a platform to promote T cell responses. DC‐MVs activate DCs and promote cross‐priming of CD8+ T cells in vitro. DC‐MVs potently amplify the expansion of adoptively transferred CD8+ T cells in vivo. DC‐MVs may serve as a potential peptide delivery system for augmenting adoptive T cell therapy.
Abstract
Cell membranes have recently gained attention as a promising drug delivery system. Here, dendritic cell membrane vesicles (DC‐MVs) are examined as a platform to promote T cell responses. Nanosized DC‐MVs are derived from DCs pretreated with monophosphoryl lipid A (MPLA), a FDA‐approved immunostimulatory adjuvant. These "mature" DC‐MVs activate DCs in vitro and increase their expression of costimulatory markers. DC‐MVs also promote cross‐priming of antigen‐specific T cells in vitro, increasing their survival and CD25 expression. In addition, these mature DC‐MVs potently augment the expansion of adoptively transferred CD8+ T cells in vivo, generating twofold to fourfold higher frequency of antigen‐specific T cells, compared with other control formulations, including "immature" DC‐MVs obtained without the MPLA pretreatment. Taken together, these results suggest that DC‐MVs are an effective delivery platform for T cell activation and may serve as a potential delivery system for improving adoptive T cell therapy.
https://ift.tt/2DVgNAS
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.